LY03017

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

LY03017, also known as LPM-526000133, is a serotonin 5-HT 2 receptor antagonist which is under development for the treatment of schizophrenia and Alzheimer's psychosis. It acts specifically as a dual serotonin 5-HT 2A receptor inverse agonist and serotonin 5-HT 2C receptor antagonist. The drug is under development by Luye Pharma Group in China. As of December 2025, it is in phase 1 clinical trials. The chemical structure of LY03017 does not yet appear to have been disclosed.

LY03017, also known as LPM-526000133, is a serotonin 5-HT 2 receptor antagonist which is under development for the treatment of schizophrenia and Alzheimer's psychosis. It acts specifically as a dual serotonin 5-HT 2A receptor inverse agonist and serotonin 5-HT 2C receptor antagonist. The drug is under development by Luye Pharma Group in China. As of December 2025, it is in phase 1 clinical trials. The chemical structure of LY03017 does not yet appear to have been disclosed.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372022092 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.